Abiopharma

Positron Corporation is a medical technology company that co-develops, manufactures, and sells state-of-the-art PET and PET-CT molecular imaging systems and clinical services to nuclear medicine healthcare providers throughout North America. Positron specializes in the field of cardiac PET imaging, the gold standard in nuclear cardiac diagnostics. Positrons innovative PET technology, clinical services and practice solutions enable healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes through providing superior cost-effective medicine. Positron has the exclusive North American distribution rights for the NeuSight PET-CT 3D 64 Slice scanner and ownership of the NeuSight FDA 510(k). Positron has also jointly developed a new Affinity PET-CT 4D 64 Slice system which it will manufacture, sell, service as well as provide clinical services and full support over the lifetime of the system. Positrons expansion to PET-CT was key to the Companys future in multiple imaging disciplines, likely setting Positron on a path for exponential growth with the NeuSight and Affinity PET-CT systems. Positrons PET-CT systems enable the Company to meet the new demands of the nuclear cardiology community and gives Positron the tools to enter and thrive in the oncology segment of the nuclear imaging market with what the Companys believes is the best product at the best price with the ability to service all healthcare providers.

Additional info from NASDAQ:
Itron Inc provides solutions that measure, manage and analyze energy and water use. It operates under the Itron brand and manages and reports under three operating segments: Device Solutions, Networked Solutions, and Outcomes. The device Solutions segment includes hardware products used for measurement, control, or sense that do not have communications capability embedded for use with broader Itron systems.The networked Solutions segment includes a combination of communicating devices, network infrastructure, and associated application software designed and sold as a complete solution. The outcome segment includes their value-added, enhanced software and services which manage, organize, analyze, and interpret data to improve decision making, maximize operational profitability.

Additional info from OTC:
Positron Corporation is a medical technology company that co-develops, manufactures, and sells state-of-the-art PET and PET-CT molecular imaging systems and clinical services to nuclear medicine healthcare providers throughout North America. Positron specializes in the field of cardiac PET imaging, the gold standard in nuclear cardiac diagnostics. Positrons innovative PET technology, clinical services and practice solutions enable healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes through providing superior cost-effective medicine. Positron has the exclusive North American distribution rights for the NeuSight PET-CT 3D 64 Slice scanner and ownership of the NeuSight FDA 510(k). Positron has also jointly developed a new Affinity PET-CT 4D 64 Slice system which it will manufacture, sell, service as well as provide clinical services and full support over the lifetime of the system. Positrons expansion to PET-CT was key to the Companys future in multiple imaging disciplines, likely setting Positron on a path for exponential growth with the NeuSight and Affinity PET-CT systems. Positrons PET-CT systems enable the Company to meet the new demands of the nuclear cardiology community and gives Positron the tools to enter and thrive in the oncology segment of the nuclear imaging market with what the Companys believes is the best product at the best price with the ability to service all healthcare providers.